Percutaneous ethanol injection therapy: A surgery-sparing treatment for primary hyperparathyroidism

Clinical Endocrinology

Volumn 69, Issue 4, 2008, Pages 542-548

  Stratigis, Spyros ^a   Stylianou, Kostas ^a   Mamalaki, Evangelia ^a   Perakis, Kostas ^a   Vardaki, Eleftheria ^a   Tzenakis, Nikolaos ^a   Katsipi, Irene ^a   Papavasiliou, Stathis ^a   Yarmenitis, Spyros ^a   Kyriazis, John ^b   Daphnis, Eugene ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b General Hospital of Chios   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM; CINACALCET; ESTROGEN; PARATHYROID HORMONE; RALOXIFENE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DYSPHONIA; ECHOGRAPHY; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL;

ADENOMA; ADMINISTRATION, CUTANEOUS; AGED; COMPLEMENTARY THERAPIES; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, PRIMARY; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; PARATHYROIDECTOMY; PROGNOSIS; TREATMENT OUTCOME;

EID: 51649083984     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03238.x     Document Type: Article

References (32)

1. Bilezikian, J.P., Potts, J.T. Jr., Fuleihan Gel, H., Kleerekoper, M., Neer, R., Peacock, M., Rastad, J., Silverberg, S.J., Udelsman, R. Wells, S.A. (2002) Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. Journal of Clinical Endocrinology and Metabolism, 87, 5353 5361.
2. Bilezikian, J.P. Silverberg, S.J. (2004) Asymptomatic Primary Hyperparathyroidism. New England Journal of Medicine, 350, 1746 1751.
3. Harman, C.R., Grant, C.S., Hay, I.D., Hurley, D.L., van Heerden, J.A., Thompson, G.B., Reading, C.C. Charboneau, J.W. (1998) Indications, technique, and efficacy of alcohol injection of enlarged parathyroid glands in patients with primary hyperparathyroidism. Surgery, 124, 1011 1019.
4. Solbiati, L., Giangrande, A., De Pra, L., Bellotti, E., Cantu, P. Ravetto, C. (1985) Percutaneous ethanol injection of parathyroid tumours under US guidance: treatment for secondary hyperparathyroidism. Radiology, 155, 607 610.
5. Monzani, F., Caraccio, N., Goletti, O., Lippolis, P.V., Casolaro, A., Del Guerra, P., Cavina, E. Miccoli, P. (1997) Five-year follow-up of percutaneous ethanol injection for the treatment of hyper functioning thyroid nodules: a study of 117 patients. Clinical Endocrinology, 46, 9 15.
6. Nakamura, M., Fuchinoue, S. Teraoka, S.I. (2003) Clinical experience with percutaneous ethanol injection therapy in haemodialysis patients with renal hyperparathyroidism. American Journal of Kidney Diseases, 42, 739 745.
7. Tanaka, M., Itoh, K., Matsushita, K. Fukagawa, M. (2005) Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on haemodialysis as evaluated by iPTH levels according to K/DOQI guidelines. Therapeutic Apheresis and Dialysis, 9, 48 52.
8. Koiwa, F., Kakuta, T., Tanaka, R. Yumita, S. (2007) Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 22, 522 528.
9. Kitaoka, M., Fukagawa, M., Ogata, E. Kurokawa, K. (1994) Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney International, 46, 1110 1117.
10. Giangrande, A., Castiglioni, A., Solbiati, L. Allaria, P. (1992) Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 7, 412 421.
11. Fukagawa, M., Kitaoka, M., Tominaga, Y., Akizawa, T., Kakuta, T., Onoda, N., Koiwa, F., Yumita, S., Kurokawa, K. Japanese Society for Parathyroid Intervention 2003) Guidelines for PEIT of the parathyroid glands in chronic dialysis patients. Nephrology Dialysis Transplantation, 18 (Suppl. 3 iii31 iii33.
12. Bennedbaek, F., Karstrup, S. Hegedus, L. (2001) Ultrasound guided laser ablation of a parathyroid adenoma. British Journal of Radiology, 74, 905 907.
13. Howell, P., Kariampuzha, S., Kipgen, W., Baker, M.Z., Tytle, T.L., Williams, G.R. Scofield, R.H. (2001) Non-surgical therapy of primary hyperparathyroidism. Journal of Oklahoma State Medical Association, 94, 561 565.
14. Verges, B., Cercueil, J.P., Pfitzenmeyer, P., Pascuad, F., Vaillant, G., Brun, J.M. Putelat, R. (1991) Percutaneous ethanol injection of parathyroid adenomas in primary hyperparathyroidism. Lancet, 337, 1421 1422.
15. Vergès, B.L., Cercueil, J.P., Jacob, D., Vaillant, G., Brun, J.M. Putelat, R. (1993) Results of ultrasonically guided percutaneous ethanol injection into parathyroid adenomas in primary hyperparathyroidism. Acta Endocrinologica, 129, 375 376.
16. Cercueil, J.P., Jacob, D., Verges, B., Holtzmann, P., Lerais, J.M. Krause, D. (1998) Percutaneous ethanol injection into parathyroid adenomas: mid- and long-term results. European Radiology, 8, 1565 1569.
17. Karstrup, S., Hegedus, L. Holm, H.H. (1993) Ultrasonically guided chemical parathyroidectomy in patients with primary hyperparathyroidism: a follow-up study. Clinical Endocrinology, 38, 523 530.
18. Karstrup, S., Transbo, I., Holm, H.H., Glenthoj, A. Hegedus. L. (1989) Ultrasound guided chemical parathyroidectomy in patients with primary hyperparathyroidism: a prospective study. British Journal of Radiology, 62, 1037 1042.
19. NIH conference 1991) Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Annals of Internal Medicine, 114, 593 597.
20. Sosa, J.A., Powe, N.R., Levine, M.A., Udelsman, R. Zeiger, M.A. (1998) Profile of a clinical practice: Thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. Journal of Clinical Endocrinology and Metabolism, 83, 2658 2665.
21. Grant, C., Thompson, G., Farley, D. van Heerden, J. (2005) Primary hyperparathyroidism surgical management since the introduction of minimally invasive parathyroidectomy. Archives of Surgery, 140, 472 479.
22. Udelsman, R. (2002) Six hundred fifty-six consecutive explorations for primary hyperparathyroidim. Annals of Surgery, 235, 665 672.
23. Norman, J.G. Politz, D.E. (2007) Safety of immediate discharge after parathyroidectomy: a prospective study of 3,000 consecutive patients. Endocrine Practice, 13, 105 113.
24. Ozbey, N., Erbil, Y., Ademolu, E., Ozarmaoan, S., Barbaros, U. Bozbora, A. (2006) Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World Journal of Surgery, 30, 321 326.
25. Wang, T.S., Ostrower, S.T. Heller, K.S. (2005) Persistently elevated parathyroid hormone levels after parathyroid surgery. Surgery, 138, 1130 1136.
26. Grey, A., Lucas, J., Horne, A., Gamble, G., Davidson, J.S. Reid, I.R. (2005) Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. Journal of Clinical Endocrinology and Metabolism, 90, 2122 2126.
27. Grey, A.B., Stapleton, J.P., Evans, M.C., Tatnell, M.A. Reid, I.R. (1996) Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Annals of Internal Medicine, 125, 360 368.
28. Chow, C.C., Chan, W.B., Li, J.K., Chan, N.N., Chan, M.H., Ko, G.T., Lo, K.W. Cockram, C.S. (2003) Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 88, 581 587.
29. Parker, C.R., Blackwell, P.J., Fairbairn, K.J. Hosking, D.J. (2002) Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. Journal of Clinical Endocrinology and Metabolism, 87, 4482 4489.
30. Rubin, M.R., Lee, K.H., McMahon, D.J. Silverberg, S.J. (2003) Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 88, 1174 1178.
31. Silverberg, S.J., Bone, H.G., Marriott, T.B., Locker, F.G., Thys-Jacobs, S., Dziem, G., Kaatz, S., Sanguinetti, E.L. Bilezikian, J.P. (1997) Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. New England Journal of Medicine, 337, 1506 1510.
32. Peacock, M., Bilezikian, J.P., Klassen, P.S., Guo, M.D., Turner, S.A. Shoback, D. (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 90, 135 141.